Company intelligence / Profile preview

Deep Apple Therapeutics

New York, New York, United Statesdeepappletx.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Deep Apple Therapeutics is a venture-backed biotech using a proprietary AI-driven platform to rapidly discover novel small-molecule drugs targeting GPCRs and other integral membrane proteins. The company leverages ensemble cryo-electron microscopy, deep learning, molecular dynamics, and ultra-large virtual chemical libraries to accelerate hit identification and lead optimization. Its initial pipeline includes preclinical programs for metabolic, inflammatory, immunology, and endocrine indications; no clinical results have been reported yet.

Therapeutic areas: ImmunologyEndocrinologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Deep Apple Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deep Apple Therapeutics.

Explore the full profile